Part1.What is baicalin powder?
Baicalin powder is a flavonoid compound extracted from the dry root of the dicotyledonous plant Scutellaria baicalensis Georgi. It is a light yellow powder at room temperature and has a bitter taste. Insoluble in methanol, ethanol, acetone, slightly soluble in chloroform and nitrobenzene, almost insoluble in water, soluble in hot acetic acid. When it meets ferric chloride, it will appear green, and when it meets lead acetate, it will form an orange precipitate. Soluble in alkali and ammonia water, initially yellow, and then dark brown soon. Has significant biological activity, has antibacterial, diuretic, anti-inflammatory, cholesterol-lowering, anti-thrombosis, relieves asthma, purging fire and detoxification, hemostasis, anti-abortion, anti-allergic and antispasmodic effects. Specific inhibitors have the effect of regulating certain diseases, and also have strong physiological efficacy of anti-cancer response.
Part2. Efficacy and use
Baicalin (Baicalin) is a flavonoid compound extracted from Scutellaria baicalensis root, which has significant biological activity, antibacterial, diuretic, anti-inflammatory, anti-allergic and antispasmodic effects, and has a strong anti-cancer response equal physiological performance. It has occupied an important position in clinical medicine. Baicalin can also absorb ultraviolet rays, scavenge oxygen free radicals, and inhibit the formation of melanin, so it can be used in both medicine and cosmetics, and is a good raw material for functional cosmetics.
Part3.Pharmacological effect
1. Anti-tumor effect
2. Anti-pathogen effect
3. Protective effect on liver damage
4. Improvement of diabetic nephropathy
5. Repair and protect against brain damage
6. Effect on retinal disease
7. Anti-allergic reaction
Part4. Indications
It is clinically used for acute, chronic persistent and chronic active hepatitis, and can also be used for nephritis, pyelonephritis and allergic diseases. This product has better ALT-lowering effect. During the period of medication, the positive titer of hepatitis B surface antigen (HBsA) decreased, but did not consolidate.
